Autologous transplantation in CML has been a focus of interest over the last few years. Determining the indications, optimal timing and method for this procedure remains controversial. One approach has been the mobilisation of Philadelphia chromosome negative (Ph؊) peripheral blood stem cells following high-dose chemotherapy as a method of purging the graft. We have described a mobilisation regimen of 7 days of hydroxyurea followed by G-CSF and have shown it to be substantially less toxic than other methods. We now report further experience with this technique in a total of 18 patients and the outcome of transplantation in seven patients using cells so-derived. Following mobilisation, approximately a third of patients had 100% Ph؊ collections and half had less than 50% Ph+ collections. All patients were 100% Ph+ prior to mobilisation. Six out of seven transplanted patients showed sustained engraftment and two of these patients became 18 and 34% Ph+ 3 months post-transplant. Five patients remain alive and well 13 to 25 months post-autograft. In conclusion, we have developed a well-tolerated regimen for Ph؊ PBSC mobilisation and have demonstrated that such cells are capable of sustained engraftment and of producing significant cytogenetic responses. Keywords: blood stem cells; chronic myeloid leukaemia; autologous stem cell transplantation; hydroxyurea; G-CSF Treatment for the majority of patients with chronic myeloid leukaemia (CML) remains unsatisfactory. The only potentially curative approach is allogeneic bone marrow transplantation which is only available to a minority of patients. Alpha-interferon (IFN) has been shown to reduce the size of the Philadelphia positive (Ph+) clone in some patients leading to a survival advantage but the ability of IFN to prolong survival in patients not achieving a major cytogenetic response remains controversial.
cells still remains of unproven benefit despite extensive experience. 4, 5 Studies do however suggest a possible survival advantage for patients treated with this procedure, a significant proportion of patients showing reduced or absent Ph+ metaphases, usually transiently, after transplant. 4, 6, 7 The evidence from IFN responders and transplanted patients implies that reduction of the Ph+ clone may correlate with improved survival.
The rationale for selecting PhϪ cells for autologous transplantation in CML is based on the presence of residual PhϪ cells in the marrow of many patients with CML especially in the early stages of their disease 8 and by the demonstration that malignant cells present in autografts can contribute to relapse. 9, 10 Purging approaches have included in vitro techniques using chemotherapy, antisense oligonucleotides and long-term liquid cultures. [11] [12] [13] An alternative in vivo approach is to take advantage of the preferential mobilisation of PhϪ cells during the early regenerative phase following myelosuppressive therapy and to collect them by apheresis. 14 This approach is however associated with considerable morbidity and some mortality. We have investigated the use of a less toxic regimen for PhϪ PBSC mobilisation using oral hydroxyurea and G-CSF. 15 We now report further experience with this technique in a total of 18 patients and the outcome of transplantation in seven patients using mobilised stem cells.
Patients and methods

Patients
Mobilisation was performed in 18 patients, all of whom had Ph+ CML. Details of age, disease state, disease duration and previous therapy are shown in Table 1 . Median age was 46 years with a range of 33-55. Eight patients were mobilised in early chronic phase within 2-7 months of diagnosis and before exposure to any other therapy apart from hydroxyurea. The remainder are a mixture of later chronic phase, second chronic phase and in one case, accelerated phase. Ethical approval was obtained for the study and informed consent was sought in all cases.
Mobilisation and harvesting
Patients were given an average of 3.5 g/m 2 hydroxyurea daily for 7 days as this dose was found to produce a useful Transplanted. Details of the age and sex of the 18 patients along with their disease status at mobilisation and the number of months since their diagnosis. An indication of the number of previous modalities of therapy is included. HU = hydroxyurea; IFN␣ = interferon ␣; DAT 3+8 = daunorubicin for 3 days with cytosine arabinoside and 6-thioguanine for 8 days as per MRC AML 10 trial protocol; CP = chronic phase; CP2 = second chronic phase; AP = accelerating phase; BC = blast crisis.
nadir in the majority. Hydroxyurea was given in the outpatient setting in all cases. The day after hydroxyurea finished, G-CSF (filgrastim) was commenced at a dose of 300 g/day subcutaneously and continued until the last day of harvesting. Apheresis was commenced only when two criteria were met, namely the appearance in the peripheral blood of CD34 + cells rising above our threshold of detection (Ͼ0.05%) and a WBC rising above 1 × 10 9 /l. Cells were collected using the mononuclear cell program on a Baxter CS3000+ (Baxter, Round Lake, IL, USA), 12 l of blood being processed daily. PBSC harvests were cryopreserved in DMSO and stored in liquid nitrogen. Samples were taken from each individual harvest prior to cryopreservation for analysis of progenitor cell content and estimation of Ph+ cell contamination.
Assessment of harvest quality
Harvest quality was assessed by determining the numbers of MNCs, CD34
+ cells and CFU-GMs. The MNC was taken from the TNC count on a Coulter STKS blood analyser after a 1:10 dilution (Coulter, Luton, UK). The MNC% of the TNC was determined by manual differential.
The CD34 + count was performed using a modification of the Baxter method on a Becton Dickinson FACScan (Oxford, UK). One million cells labelled with CD34-PE and CD45-FITC (Becton Dickinson) were resuspended in FACSFlow containing propidium iodide (PI). Cells were analysed using LYSIS II software. A live gate was set on viable leucocytes (CD45 + , PI Ϫ ), 50-200 000 events were collected and CD34
+ events defined by their CD34 expression and forward and side scatter characteristics. The collection of 50-200 000 events gives a threshold of detection of 0.05% in our hands.
CFU-GM assays were performed in a semi-solid culture system in which 5 × 10 5 MNC were suspended in liquid medium (MEM alpha; Gibco, Life Technologies, Paisley, UK) to which was added a mixture of molten agar, foetal calf serum, and 5637 conditioned medium. Assays were plated in triplicate in 1 ml aliquots into 35 mm petri dishes, each containing 10 5 MNC. Colonies of typical appearance and of Ͼ50 cells were counted after 10-14 days incubation at 37°C in 5% CO 2 .
Detection of Ph+ cells
Contaminating Ph+ cells were detected by conventional cytogenetics, FISH and PCR.
Cytogenetic analysis was carried out on fresh PBSC samples following incubation in culture medium (RPMI + glutamine + foetal calf serum) for 48 h, the last 17 h of this in the presence of 0.2 g/ml colcemid. Cells were then washed, incubated with 0.075 m KCl for 15 min and fixed with a 3:1 methanol:acetic acid mixture. G-banding was performed on the cells prepared in this way and as many intact and assessable metaphases as were produced were examined microscopically for the presence of the Philadelphia chromosome.
FISH was carried out using the m-bcr/abl (minor breakpoint) translocation DNA probe (Oncor, Chester-leStreet, UK) following the manufacturer's instructions with minor modifications. Slides were viewed with a triple bandpass filter (Oncor) which enables simultaneous viewing of the FITC (green), rhodamine (red) signals and the DAPI (blue) counterstain. A combined red and green signal (often appearing yellow) indicates the translocation. A minimum of 50 cells were assessed. Marrow slides from CML patients at presentation were used as positive controls. Samples from normal marrows and patients with PhϪ acute leukaemias were used as negative controls and produced a background false positive rate of 0-4% resulting from random juxtaposition of the signals.
A nested PCR technique was used to detect the presence of a fusion transcript from the abnormal BCR-ABL gene. 16 RNA was extracted using a commercial preparation based on the acid guanidinium phenol chloroform method (Trizol; Life Technologies) and reverse transcribed using random hexamers as primers and MoMLV reverse transcriptase. These steps were controlled by a single round PCR for the ABL gene to demonstrate that adequate quality cDNA had been produced. Nested PCR was performed on 1 l of the cDNA using p210-specific primers and the products visualised on a 2% agarose gel by ethidium bromide staining. The B3A2 product yielded a 458 bp band and the B2A2 a 383 bp band. Controls included 1/100 dilutions of known positive B2A2 and B3A2 cDNAs, two known negative cDNAs and RT and PCR blanks. The sensitivity of the test in our hands is of the order of 1 in 10. Table 2 summarises the patients' details regarding hydroxyurea doses, timing of harvesting, number of aphereses and quality of harvest. The median interval from diagnosis to mobilisation was 11 months (range, 2-48 months). WBC nadir was reached around day +3 with a median WBC nadir of 0.6 × 10 9 /l (range 0.2-1.6). The median interval between completion of hydroxyurea and harvest was 14 days (range Table 2 Mobilisation and harvesting ) and colony-forming unit granulocyte-macrophage numbers (CFU-GM). HO = hydroxyurea; WBC = total white blood cell count. [10] [11] [12] [13] [14] [15] [16] [17] [18] . The time to recovery was remarkably constant and only one patient differed significantly from the rest of the group. A median number of 3.5 aphereses was required to achieve adequate cell numbers (range [1] [2] [3] [4] [5] [6] + cells/kg which we would normally consider a relative contraindication to transplant.
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Results
Mobilisation
Toxity was significantly reduced compared to other regimens. [17] [18] [19] One third of patients were treated entirely as outpatients with no episode of neutropenic fever. The others have been admitted with fever which has responded to standard broad spectrum antibiotics in all but one case, who went on to receive amphotericin B although fungal infection was not documented. A median 9 days was spent in hospital. Median time to haematological recovery was 14 days (range 6-18). Twelve of the 18 patients required an average of 2 units of blood and 4 units of platelets, the remaining six needed no blood product support. Sideeffects directly related to hydroxyurea have been skin rashes and oral mucositis affecting about half of the patients. The mucositis that occurred was mild (WHO grade 1, erythema and soreness only). Nausea or vomiting was not a feature in any of our patients. One patient reported some thinning of their hair but no alopecia was seen.
The cytogenetic data on the PBSC collections are detailed in Table 3 . Fourteen of the 18 patients were evaluable by conventional cytogenetics. All had 100% Ph+ metaphases in their marrow prior to mobilisation. Four (28.5%) had a complete response and a further four (28.5%) a major response (defined as Ͼ0% and Ͻ35% Ph+ metaphases). One patient had a 46% response and the remaining five showed little or no response. FISH was a useful supplement to cytogenetics. It gave information on two further patients both of whom had significant responses but in whom conventional cytogenetics failed for technical reasons. It also demonstrated that in harvests that were negative by cytogenetics there were 1-19% positive cells by FISH. PCR was positive in all 10 patients analysed.
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PBSC transplantation
A total of seven patients, median age 46 years (range, 33-55), subsequently underwent autologous transplantation using only PBSCs mobilised following hydroxyurea/G-CSF. The median duration of disease prior to harvest was 30 months for these patients (range, 8-48 months). None of the patients had achieved a cytogenetic response at the time of mobilisation or at transplantation. Prior treatment included hydroxyurea alone (two patients), hydroxyurea and interferon (four patients) and busulphan, hydroxyurea and interferon (one patient). Two of the patients were transplanted after transformation to blast crisis whilst the remaining five were in chronic phase. Conditioning varied with some patients being given busulphan (16 mg/kg/day for 4 days) and cyclophosphamide (60 mg/kg/day for 2 days) and others busulphan alone. Post-transplant G-CSF was not used. The median MNC dose reinfused was 2.8 × 10 8 /kg (range 1.9-7.7) and the median CD34 + cell dose 3.4 × 10 6 /kg (range 1.4-6.7). By conventional cytogenetics, five of the reinfused harvests had successfully been assessed, two of the harvests were completely PhϪ and two showed a major cytogenetic response (2.4% and 28.6% Ph+ metaphases). FISH gave further information on the two reinfused harvests which were not assessable by conventional cytogenetics for technical reasons and both showed significant responses (10% and 32% Ph positive).
Details of engraftment, cytogenetic evaluation and follow up of the seven transplanted patients are shown in Table 4 . Engraftment of neutrophils to Ͼ0.5 × 10 9 /l occurred at a median of 17 days and platelets to Ͼ20 × 10 9 /l at 21 days. One patient aged 55 years failed to make a clinical or haematological recovery from the procedure despite receiving 3 × 10 6 CD34+ cells/kg and died of venoocclusive disease (VOD) and engraftment failure 3 months after return of PBSCs. This was despite the infusion of additional back-up buffy coat cells. The other six patients all left hospital within 33 days without any clinical problems beyond those that would be considered routine following a high-dose procedure. One of the two patients in blast crisis achieved stable chronic phase for 5 months but then relapsed. He was given a second autograft using buffy coat cells collected at diagnosis but failed to attain a second remission and died from his disease 8 months after the original PBSCT. The other patient who was in blast crisis at transplant is still alive 25 months post autograft although their disease is now in accelerated phase. The other four patients remain in chronic phase and are alive and well 13 to 25 months post-autograft.
Two patients, who were 100% Ph+ pretransplant, became 18 and 34% Ph+ 3 months post-transplant. Their respective grafts had shown 10% Ph+ contamination by FISH (cytogenetics failed) in the former and 0% Ph+ metaphases by conventional cytogenetics and 19% Ph+ contamination by FISH in the latter. These patients are now 86% Ph+ 13 months, and 50% Ph+ 14 months post-transplant, respectively. Five patients regenerated with 100% Ph+ cells at 3 months. The graft Ph+ contamination was less than 50% in four of these patients.
Discussion
The role of autologous transplantation in the management of CML is still being evaluated and its place is by no means Engraftment and follow-up for the transplanted patients. The disease stage at time of transplant is shown for each patient alongside the number of days until neutrophil and platelet recovery. The % positivity for the Ph chromosome in the marrow within 3 months after the procedure is indicated and the current clinical status, treatment and months post-transplant is shown in the last column. N = neutrophil count ×10 9 /l; Plt = platelet count ×10 9 /l; BM = bone marrow; CP = chronic phase; AP = accelerating phase; BC = blast crisis; NR = not recorded; IFN = interferon; VOD = veno-occlusive disease; HU = hydroxyurea.
established although there is a suggestion of a survival advantage in several clinical trials. 4, 5 Manipulation of the graft to increase the proportion of putatively normal PhϪ cells is theoretically attractive in order to help reestablish PhϪ haemopoiesis after myeloablative therapy. There is as yet no evidence to suggest that this will be of benefit and only large-scale prospective comparative studies could be expected to provide any.
The preferential release of PhϪ progenitor cells in some patients during the early phase of post-chemotherapy regeneration provides a partially purged harvest product for subsequent autologous transplantation.
Optimal methods for PhϪ PBSC mobilisation in CML and the timing of such procedures remain to be adequately defined. It is clear that the results of stem cell mobilisation are superior when carried out earlier in the disease both in terms of the number of stem cells collected and the proportion of harvests that are PhϪ. 17, 20 We have evaluated an oral regimen of hydroxyurea and G-CSF for collection of these cells in the early recovery phase after myelosuppression. The toxicity of the procedure, although not insignificant, was considerably less than that of published intravenous schedules 17, 19, 20 with one third of patients being treated entirely as outpatients, a median time to haematological recovery of 14 days and with no prolonged cytopenias or fatalities. This contrasts with intravenous mobilisation regimens such as idarubicin/cytarabine/etoposide (ICE) 21 and idarubicin/ cytarabine 20 which have a mortality of approximately 5% and a cytopenic period of at least 3 weeks for the majority of patients with occasional very protracted cytopenias.
The cytogenetic data from the PBSC harvest material shows that over half (56%) of the patients have shown a complete (28%) or major (28%) cytogenetic response to mobilisation using our regimen. These results are very similar to the data published using intravenous regimens such as ICE 21 (complete 31%, major 17%) and idarubicin/ cytarabine 20 (complete 43%, major 16% of individual harvests).
PBSCs mobilised with hydroxyurea are clearly capable of sustained engraftment as demonstrated in six out of the seven patients transplanted and it is clear that some patients regenerate partially PhϪ haemopoiesis. Two patients who were 100% Ph+ pretransplant became 18 and 34% Ph+ 3 months post-transplant, representing major responses. At 1 year post-transplant these patients had bone marrows showing 86 and 50% Ph+, respectively, indicating an increase in the size of the Ph+ clone. Direct comparison with other data from autotransplants using PhϪ PBSCs mobilised with intravenous chemotherapy is difficult as the data is still immature and relates to small numbers of patients. Chalmers et al 20 recently reported PBSC mobilisation using idarubicin and cytarabine in 40 patients with 20 subsequently undergoing PBSC transplantation. Overall mortality was high at 5% (2/40) during mobilisation and 15% (3/20) after the transplant. Post-transplant cytogenetic analysis at 1-3 months showed that 5/15 (33%) had a major cytogenetic response and 5/15 (33%) a partial response. Carella et al In conclusion, we have developed a method for PhϪ PBSC mobilisation in CML that appears to be less toxic than intravenous regimens. This regimen may therefore be an attractive alternative particularly as this procedure may best be carried out early in the disease process when toxic treatments are harder to justify. Furthermore, we have demonstrated that engraftment is satisfactory and sustained in such patients. Our results suggest a similar efficacy in terms of mobilisation to other regimens although longer followup is required before direct comparisons can be made.
Determining the place, if any, of autotransplantation in this disease and modifications to the procedure remain problematic. The current UK Medical Research Council study MRC CML IV 22 will hopefully provide information as to whether an autologous bone marrow transplant results in improved survival in patients with CML not responding to interferon.
